Payment overview · 2025
General Payments
$1,091.03
49 reported records · 16 companies
Healthcare provider profile · identity verified
Eric Lawrence, DO
Allopathic & Osteopathic Physicians|Family Medicine · CASPER, WY · NPI 1326223751
Verified facts
What the public records show
CMS Open Payments records show Eric Lawrence, DO received $1,091.03 in general payments during 2025 across 49 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fanapt, Mounjaro, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.73 | 26.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $180.85 | 16.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $157.80 | 14.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $106.62 | 9.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.72 | 5.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.71 | 5.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $41.95 | 3.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.55 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.19 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.53 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.09 | 1.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.53 | 1.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $19.87 | 1.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.24 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,059.05 | 47 |
| Education | $31.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $157.80 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $139.33 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.27 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.68 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $86.25 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.29 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $68.72 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.15 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $62.71 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.55 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FANAPT fanapt |
2025 | Fanapt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 739 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 115 |
| Eliquis | Apixaban | 570 | 57 |
| Gabapentin | Gabapentin | 469 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 88 |
| Furosemide | Furosemide | 359 | 54 |
| Lisinopril | Lisinopril | 331 | 75 |
| Potassium Chloride | Potassium Chloride | 304 | 51 |
| Losartan Potassium | Losartan Potassium | 292 | 66 |
| Trazodone Hcl | Trazodone Hcl | 286 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 217 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 51 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 39 |
| Sertraline Hcl | Sertraline Hcl | 204 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 43 |
| Omeprazole | Omeprazole | 189 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 28 |
| Metformin Hcl Er | Metformin Hcl | 174 | 45 |
| Tramadol Hcl | Tramadol Hcl | 162 | 36 |
| Lorazepam | Lorazepam | 146 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 22 |
| Baclofen | Baclofen | 136 | 20 |
| Bupropion Xl | Bupropion Hcl | 128 | 27 |
| Aripiprazole | Aripiprazole | 126 | 17 |
| Warfarin Sodium | Warfarin Sodium | 121 | 11 |
| Allopurinol | Allopurinol | 114 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 34 |
| Montelukast Sodium | Montelukast Sodium | 103 | 24 |
| Donepezil Hcl | Donepezil Hcl | 102 | 20 |
| Buspirone Hcl | Buspirone Hcl | 97 | 21 |
| Simvastatin | Simvastatin | 96 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 24 |
| Carvedilol | Carvedilol | 91 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 16 |
| Olanzapine | Olanzapine | 84 | 17 |
| Finasteride | Finasteride | 83 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 24 |
| Metformin Hcl | Metformin Hcl | 80 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 21 |
| Divalproex Sodium | Divalproex Sodium | 78 | suppressed |
| Ozempic | Semaglutide | 77 | 11 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Prednisone | Prednisone | 76 | 25 |
| Spironolactone | Spironolactone | 73 | 19 |
| Latanoprost | Latanoprost | 69 | 11 |
| Sucralfate | Sucralfate | 69 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 69 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 11 |
| Mirtazapine | Mirtazapine | 64 | 11 |
| Levetiracetam | Levetiracetam | 63 | 11 |
| Meloxicam | Meloxicam | 63 | 20 |
| Clonazepam | Clonazepam | 62 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 16 |
| Rexulti | Brexpiprazole | 58 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 17 |
| Memantine Hcl | Memantine Hcl | 57 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | suppressed |
| Torsemide | Torsemide | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Atenolol | Atenolol | 51 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 29 |
| Azithromycin | Azithromycin | 42 | 32 |
| Pregabalin | Pregabalin | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Cephalexin | Cephalexin | 41 | 24 |
| Linzess | Linaclotide | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 26 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 32 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Risperidone | Risperidone | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Clozapine | Clozapine | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 18 |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 15 |
| Buprenorphine | Buprenorphine | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 11 |
| Np Thyroid | Thyroid,pork | 19 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fanapt | Iloperidone | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,091.03 · 49 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, Briviact, Dexcom G6 Transmitter, EVENITY, FANAPT, Kerendia, Korlym, LEQVIO, MOUNJARO, PROLIA, QULIPTA, REXULTI, SX-ONE MICROKNIFE, UBRELVY, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fanapt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error